Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 12
Submit an article Journal homepage
134
Views
74
CrossRef citations to date
0
Altmetric
Research Article

Thalidomide in Myelofibrosis with Myeloid Metaplasia: A Pooled-analysis of Individual Patient Data from Five Studies

Giovanni Barosi Laboratorio di Informatica Medica, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy
,
Michelle Elliott Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
,
Letizia Canepa Department of Hematology and Oncology, Azienda Ospedaliera San Martino, Genova, Italy
,
Filippo Ballerini Department of Hematology and Oncology, Azienda Ospedaliera San Martino, Genova, Italy
,
Pier Paolo Piccaluga Institute of Hematology and Clinical Oncology “L.&A. Seragnoli”, University of Bologna, Bologna, Italy
,
Giuseppe Visani Department of Hematology, San Salvatore Hospital, Pesaro, Italy
,
Monia Marchetti Laboratorio di Informatica Medica, IRCCS Policlinico S. Matteo, 27100 Pavia, Italy
,
Gabriele Pozzato Unità Clinico Operativa Medicina Clinica, Ospedale di Cattinara, 34100 Trieste, Italy
,
Francesca Zorat Unità Clinico Operativa Medicina Clinica, Ospedale di Cattinara, 34100 Trieste, Italy
&
Ayalew Tefferi Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
 show all
Pages 2301-2307 | Published online: 01 Jul 2009

Citations (74)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (18)

Musa Yilmaz & Srdan Verstovsek. (2022) Managing patients with myelofibrosis and thrombocytopenia. Expert Review of Hematology 15:3, pages 233-241.
Read now
Giulia Benevolo, Elena M. Elli, Paola Guglielmelli, Alessandra Ricco & Margherita Maffioli. (2020) Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy. Leukemia & Lymphoma 61:7, pages 1535-1547.
Read now
Minghui Duan & Daobin Zhou. (2019) Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone. Hematology 24:1, pages 516-520.
Read now
Prithviraj Bose & Srdan Verstovsek. (2016) Myelofibrosis: an update on drug therapy in 2016. Expert Opinion on Pharmacotherapy 17:18, pages 2375-2389.
Read now
Francisco Cervantes, Juan-Gonzalo Correa & Juan Carlos Hernandez-Boluda. (2016) Alleviating anemia and thrombocytopenia in myelofibrosis patients. Expert Review of Hematology 9:5, pages 489-496.
Read now
Samah Alimam & Claire Harrison. (2016) Is there a role for pomalidomide in the treatment of myelofibrosis?. Expert Opinion on Orphan Drugs 4:5, pages 501-509.
Read now
Krisstina L Gowin & Ruben A Mesa. (2015) Profile of pomalidomide and its potential in the treatment of myelofibrosis. Therapeutics and Clinical Risk Management 11, pages 549-556.
Read now
Yan Beauverd, Donal P McLornan & Claire N Harrison. (2015) Pacritinib: a new agent for the management of myelofibrosis?. Expert Opinion on Pharmacotherapy 16:15, pages 2381-2390.
Read now
Krisstina Gowin & Ruben Mesa. (2013) Emerging therapies for the treatment of chronic Philadelphia chromosome-negative myeloproliferative neoplasm-associated myelofibrosis. Expert Opinion on Investigational Drugs 22:12, pages 1603-1611.
Read now
Kathryn B Bollin, Holly L Geyer & Ruben A Mesa. (2013) Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis. Expert Opinion on Orphan Drugs 1:7, pages 539-547.
Read now
Francisco Cervantes & Alejandra Martinez-Trillos. (2013) Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opinion on Pharmacotherapy 14:7, pages 873-884.
Read now
Alen Ostojic, Radovan Vrhovac & Srdan Verstovsek. (2012) Ruxolitinib for the treatment of myelofibrosis: its clinical potential. Therapeutics and Clinical Risk Management 8, pages 95-103.
Read now
Raoul Tibes, James M Bogenberger & Ruben A Mesa. (2012) Recent developments in myelofibrosis. Blood and Lymphatic Cancer: Targets and Therapy 2, pages 125-136.
Read now
Ali Tabarroki & Ramon V Tiu. (2012) Immunomodulatory agents in myelofibrosis. Expert Opinion on Investigational Drugs 21:8, pages 1141-1154.
Read now
Sonia Vallet, Mathias Witzens-Harig, Dirk Jaeger & Klaus Podar. (2012) Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opinion on Pharmacotherapy 13:4, pages 473-494.
Read now
Raoul Tibes & Ruben A. Mesa. (2011) Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?. Leukemia & Lymphoma 52:7, pages 1178-1187.
Read now
Giovanni Barosi, Vittorio Rosti & Alessandro M Vannucchi. (2011) Therapeutic approaches in myelofibrosis. Expert Opinion on Pharmacotherapy 12:10, pages 1597-1611.
Read now
Ruben A Mesa & Ayalew Tefferi. (2009) Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opinion on Emerging Drugs 14:3, pages 471-479.
Read now

Articles from other publishers (56)

Donal P. McLornan, Bethan Psaila, Joanne Ewing, Andrew Innes, Siamak Arami, Jessica Brady, Nauman M. Butt, Catherine Cargo, Nicholas C. P. Cross, Sebastian Francis, Rebecca Frewin, Mamta Garg, Anna L. Godfrey, Anna Green, Alesia Khan, Steve Knapper, Jonathan Lambert, Andrew McGregor, Mary Frances McMullin, Jyoti Nangalia, Pratap Neelakantan, Claire Woodley, Adam Mead, Tim C. P. Somervaille & Claire N. Harrison. (2023) The management of myelofibrosis: A British Society for Haematology Guideline. British Journal of Haematology.
Crossref
Samuel B. Reynolds & Kristen Pettit. (2022) New approaches to tackle cytopenic myelofibrosis. Hematology 2022:1, pages 235-244.
Crossref
Shiqiang Qu, Zefeng Xu, Tiejun Qin, Bing Li, Lijuan Pan, Jia Chen, Xin Yan, Junying Wu, Yudi Zhang, Peihong Zhang, Robert Peter Gale & Zhijian Xiao. (2022) Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study. Hematological Oncology 40:4, pages 787-795.
Crossref
Aaron T. GerdsJason GotlibHaris AliPrithviraj BoseAndrew DunbarAmro ElshouryTracy I. GeorgeKrishna GundaboluElizabeth HexnerGabriela S. HobbsTania JainCatriona JamiesonPaul R. KaesbergAndrew T. KuykendallYazan MadanatBrandon McMahonSanjay R. MohanKalyan V. NadimintiStephen OhAnimesh PardananiNikolai PodoltsevLindsay ReinRachel SalitBrady L. SteinMoshe TalpazPankit VachhaniMartha WadleighSarah WallDawn C. Ward, Mary Anne BergmanCindy Hochstetler. (2022) Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 20:9, pages 1033-1062.
Crossref
Dahniel Sastow, John Mascarenhas & Douglas Tremblay. (2022) Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment. Clinical Lymphoma Myeloma and Leukemia 22:7, pages e507-e520.
Crossref
Mohamed Ayman El-Zahabi, Helmy Sakr, Khaled. El-Adl, Mohamed Zayed, Adel S. Abdelraheem, Sally I. Eissa, Hazem Elkady & Ibrahim H. Eissa. (2020) Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents. Bioorganic Chemistry 104, pages 104218.
Crossref
Prithviraj Bose & Srdan Verstovsek. (2018) Management of Myelofibrosis-Related Cytopenias. Current Hematologic Malignancy Reports 13:3, pages 164-172.
Crossref
Douglas Tremblay, Bridget Marcellino & John Mascarenhas. (2017) Pharmacotherapy of Myelofibrosis. Drugs 77:14, pages 1549-1563.
Crossref
Paula de Melo Campos. (2016) Primary myelofibrosis: current therapeutic options. Revista Brasileira de Hematologia e Hemoterapia 38:3, pages 257-263.
Crossref
Rita Campanelli, Gabriela Fois, Paolo Catarsi, Valentina Poletto, Laura Villani, Benedetta Gaia Erba, Luigi Maddaluno, Basilio Jemos, Silvia Salmoiraghi, Paola Guglielmelli, Vittorio Abbonante, Christian Andrea Di Buduo, Alessandra Balduini, Alessandra Iurlo, Giovanni Barosi, Vittorio Rosti & Margherita Massa. (2016) Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLOS ONE 11:6, pages e0156990.
Crossref
Ki-Seong Eom. (2016) Evolution of Myelofibrosis Treatment. The Korean Journal of Medicine 90:4, pages 293-297.
Crossref
Srdan VerstovsekHolly L Geyer & Ruben A Mesa. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment 50 68 .
Srdan VerstovsekFrancisco Cervantes & Arturo Pereira. 2015. Novel Insights into Myelofibrosis Pathophysiology and Treatment. Novel Insights into Myelofibrosis Pathophysiology and Treatment 124 135 .
Raoul Tibes & Ruben A Mesa. (2014) Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies. Journal of Hematology & Oncology 7:1.
Crossref
Francisco Cervantes. (2014) How I treat myelofibrosis. Blood 124:17, pages 2635-2642.
Crossref
Gunnar Birgegård. (2014) Does anything work for anaemia in myelofibrosis?. Best Practice & Research Clinical Haematology 27:2, pages 175-185.
Crossref
Jyoti Malhotra, Marina Kremyanskaya, Emily Schorr, Ronald Hoffman & John Mascarenhas. (2014) Coexistence of Myeloproliferative Neoplasm and Plasma-Cell Dyscrasia. Clinical Lymphoma Myeloma and Leukemia 14:1, pages 31-36.
Crossref
John Mascarenhas & Ronald Hoffman. (2013) A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood 121:24, pages 4832-4837.
Crossref
LIAN GU, LI SU, QING CHEN, JUANJUAN XIE, GUANGLIANG WU, YAN YAN, BAOYUN LIANG, JINJING TAN & NONG TANG. (2013) Ruxolitinib for myelofibrosis. Experimental and Therapeutic Medicine 5:3, pages 927-931.
Crossref
John T. Reilly. 2013. Neoplastic Diseases of the Blood. Neoplastic Diseases of the Blood 155 168 .
Raoul Tibes, James M. Bogenberger, Kasey L. Benson & Ruben A. Mesa. (2012) Current Outlook on Molecular Pathogenesis and Treatment of Myeloproliferative Neoplasms. Molecular Diagnosis & Therapy 16:5, pages 269-283.
Crossref
Francisco CervantesBrigitte DupriezFrancesco PassamontiAlessandro M. VannucchiEnrica MorraJohn T. ReillyJean-Loup DemoryElisa RumiPaola GuglielmelliElisa RoncoroniAyalew TefferiArturo Pereira. (2012) Improving Survival Trends in Primary Myelofibrosis: An International Study. Journal of Clinical Oncology 30:24, pages 2981-2987.
Crossref
Raoul Tibes, Gurcharan Singh Khera & Ruben A. Mesa. 2012. Textbook of Uncommon Cancer. Textbook of Uncommon Cancer 647 658 .
I. N. Prokopenko. (2011) MYELOPROLIFERATION FEATURES IN MYELOFIBROSIS WITH MYELOID METAPLASIA IN PERSONS, AFFECTED BY RADIATION AFTER CHERNOBYL DISASTER. Health and Ecology Issues:2S, pages 76-79.
Crossref
Raoul Tibes & Ruben Mesa. (2011) JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data. Clinical Investigation 1:12, pages 1681-1693.
Crossref
K H Begna, R A Mesa, A Pardanani, W J Hogan, M R Litzow, R F McClure & A Tefferi. (2010) A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 25:2, pages 301-304.
Crossref
Giovanni Barosi. 2011. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms 117 138 .
John Mascarenhas & Ronald Hoffman. (2010) Myeloproliferative Neoplasms: New Translational Therapies. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 77:6, pages 667-683.
Crossref
Ruben A. Mesa, Animesh D. Pardanani, Kebede Hussein, Wenting Wu, Susan Schwager, Mark R. Litzow, William J Hogan & Ayalew Tefferi. (2010) Phase1/‐2 study of Pomalidomide in myelofibrosis. American Journal of Hematology 85:2, pages 129-130.
Crossref
Ruben A. Mesa. (2010) New Drugs for the Treatment of Myelofibrosis. Current Hematologic Malignancy Reports 5:1, pages 15-21.
Crossref
Omar I. Abdel-WahabRoss L. Levine. (2009) Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment. Annual Review of Medicine 60:1, pages 233-245.
Crossref
Francisco Cervantes, Mireia Camós, Rolando Vallansot & Alberto Alvarez-Larrán. (2008) Conventional and New Treatment Modalities in Myelofibrosis and the Current Role of Transplantation. Clinical Leukemia 2:1, pages 39-45.
Crossref
Magda Melchert & Alan F. List. 2008. Antiangiogenic Agents in Cancer Therapy. Antiangiogenic Agents in Cancer Therapy 457 473 .
Francisco Cervantes. (2007) Myelofibrosis: biology and treatment options. European Journal of Haematology 79:s68, pages 13-17.
Crossref
Francis J. Giles, Alan F. List, Michael Carroll, Jorge E. Cortes, Joyce Valickas, Bee-Lian Chen, Eric Masson, Christian Jacques, Dirk Laurent, Maher Albitar, Eric J. Feldman & Gail J. Roboz. (2007) PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia Research 31:7, pages 891-897.
Crossref
Ruben A. Mesa, Alfonso Quintás-Cardama & Srdan Verstovsek. (2007) Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasia. Current Hematologic Malignancy Reports 2:1, pages 25-33.
Crossref
John T. Reilly. 2007. Myeloproliferative Disorders. Myeloproliferative Disorders 253 276 .
Hans Carl Hasselbalch & Caroline H. Riley. (2006) Statins in the treatment of polycythaemia vera and allied disorders: An antithrombotic and cytoreductive potential?. Leukemia Research 30:10, pages 1217-1225.
Crossref
Cecilia Arana-Yi, Alfonso Quintás-Cardama, Francis Giles, Deborah Thomas, Antonio Carrasco-Yalan, Jorge Cortes, Hagop Kantarjian & Srdan Verstovsek. (2006) Advances in the Therapy of Chronic Idiopathic Myelofibrosis. The Oncologist 11:8, pages 929-943.
Crossref
Ruben A. Mesa, Giovanni Barosi, Francisco Cervantes, John T. Reilly & Ayalew Tefferi. (2006) Myelofibrosis with myeloid metaplasia: Disease overview and non-transplant treatment options. Best Practice & Research Clinical Haematology 19:3, pages 495-517.
Crossref
Ruben A Mesa. (2006) Practical management of classical myeloproliferative disorder patients: a clinician’s guide. Future Oncology 2:4, pages 515-524.
Crossref
John T Reilly. (2006) Idiopathic myelofibrosis: pathogenesis to treatment. Hematological Oncology 24:2, pages 56-63.
Crossref
Deborah A. Thomas, Francis J. Giles, Maher Albitar, Jorge E. Cortes, Srdan Verstovsek, Stefan Faderl, Susan M. O'Brien, Guillermo Garcia-Manero, Michael J. Keating, Sherry Pierce, Jerome Zeldis & Hagop M. Kantarjian. (2006) Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer 106:9, pages 1974-1984.
Crossref
Howard A. BurrisIIIIII. (2006) Low-Molecular-Weight Heparins in the Treatment of Cancer-Associated Thrombosis: A New Standard of Care?. Seminars in Oncology 33, pages 3-16.
Crossref
Giovanni Barosi & Ronald Hoffman. (2005) Idiopathic Myelofibrosis. Seminars in Hematology 42:4, pages 248-258.
Crossref
S. Aksoy, H. Abali, S. Kilickap, M. Dincer & M. Erman. (2005) Persistent myeloproliferative reaction to intrauterine thalidomide exposure. Clinical and Laboratory Haematology 27:3, pages 211-212.
Crossref
Mandeep Walia, Rajesh Mehta, Premila Paul, Sumita Saluja, Sujala Kapoor & Monika Sharma. (2005) Idiopathic Myelofibrosis With Generalized Periostitis in a 4-Year-Old Girl. Journal of Pediatric Hematology/Oncology 27:5, pages 278-282.
Crossref
Francisco Cervantes. (2005) Modern management of myelofibrosis. British Journal of Haematology 128:5, pages 583-592.
Crossref
G. Damaj, R. Bouabdallah, N. Vey, K. Bilger, M. Mohty & J. A. Gastaut. (2005) Single-agent thalidomide induces response in T-cell lymphoma. European Journal of Haematology 74:2, pages 169-171.
Crossref
Bryan T. Hennessy, Deborah A. Thomas, Francis J. Giles, Hagop Kantarjian & Srdan Verstovsek. (2004) New approaches in the treatment of myelofibrosis. Cancer 103:1, pages 32-43.
Crossref
Meletios A. Dimopoulos & Vagelis Eleutherakis-Papaiakovou. (2004) Adverse effects of thalidomide administration in patients with neoplastic diseases. The American Journal of Medicine 117:7, pages 508-515.
Crossref
Shaji Kumar, Thomas E. Witzig & S. Vincent Rajkumar. (2004) Thalidomide: Current Role in the Treatment of Non-Plasma Cell Malignancies. Journal of Clinical Oncology 22:12, pages 2477-2488.
Crossref
Giovanni Barosi, Rosti Vittorio, Massa Margherita, Viarengo G. Luca, Pecci Alessandro, Necchi Vittorio, Ramaioli Isabella, Campanelli Rita, Marchetti Monia, Bazzan Mario & Magrini Umberto. (2004) Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology 124:5, pages 618-625.
Crossref
Monia MarchettiGiovanni BarosiFrancesca BalestriGianluca ViarengoSara GentiliSara BarulliJean-Loup DemoryFiorella IlariucciAntonio VolpeDominique BordessouleAlberto GrossiMarie Caroline Le Bousse-KerdilesAndrea CaenazzoAlessandro PecciAntonietta FalconeGiorgio BrocciaCesarina BendottiFredric BauduerFrancesco BuccisanoBrigitte Dupriez. (2004) Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial. Journal of Clinical Oncology 22:3, pages 424-431.
Crossref
Giovanni Barosi. (2003) Myelofibrosis with myeloid metaplasia. Hematology/Oncology Clinics of North America 17:5, pages 1211-1226.
Crossref
Jerry L. Spivak, Giovanni Barosi, Gianni Tognoni, Tiziano Barbui, Guido Finazzi, Roberto Marchioli & Monia Marchetti. (2003) Chronic Myeloproliferative Disorders. Hematology 2003:1, pages 200-224.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.